Literature DB >> 22072721

Long-term antibody and immune memory response induced by pulmonary delivery of the influenza Iscomatrix vaccine.

Ana Vujanic1, Kenneth J Snibson, Janet L K Wee, Stirling J Edwards, Martin J Pearse, Jean-Pierre Y Scheerlinck, Philip Sutton.   

Abstract

Pulmonary delivery of an influenza Iscomatrix adjuvant vaccine induces a strong systemic and mucosal antibody response. Since an influenza vaccine needs to induce immunological memory that lasts at least 1 year for utility in humans, we examined the longevity of the immune response induced by such a pulmonary vaccination, with and without antigen challenge. Sheep were vaccinated in the deep lung with an influenza Iscomatrix vaccine, and serum and lung antibody levels were quantified for up to 1 year. The immune memory response to these vaccinations was determined following antigen challenge via lung delivery of influenza antigen at 6 months and 1 year postvaccination. Pulmonary vaccination of sheep with the influenza Iscomatrix vaccine induced antigen-specific antibodies in both sera and lungs that were detectable until 6 months postimmunization. Importantly, a memory recall response following antigenic challenge was detected at 12 months post-lung vaccination, including the induction of functional antibodies with hemagglutination inhibition activity. Pulmonary delivery of an influenza Iscomatrix vaccine induces a long-lived influenza virus-specific antibody and memory response of suitable length for annual vaccination against influenza.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22072721      PMCID: PMC3255945          DOI: 10.1128/CVI.05265-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  14 in total

1.  Influenza vaccines.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2002-07-12

2.  Inhalative vaccination with pneumococcal polysaccharide in healthy volunteers.

Authors:  Manuela Menzel; Bernhard Muellinger; Norbert Weber; Karl Haeussinger; Loems Ziegler-Heitbrock
Journal:  Vaccine       Date:  2005-10-17       Impact factor: 3.641

Review 3.  ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines.

Authors:  Debbie Drane; Charmaine Gittleson; Jeff Boyle; Eugene Maraskovsky
Journal:  Expert Rev Vaccines       Date:  2007-10       Impact factor: 5.217

Review 4.  Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant.

Authors:  Eugene Maraskovsky; Max Schnurr; Nick S Wilson; Neil C Robson; Jeff Boyle; Debbie Drane
Journal:  Immunol Cell Biol       Date:  2009-04-21       Impact factor: 5.126

5.  Combined mucosal and systemic immunity following pulmonary delivery of ISCOMATRIX adjuvanted recombinant antigens.

Authors:  Ana Vujanic; Janet L K Wee; Kenneth J Snibson; Stirling Edwards; Martin Pearse; Charles Quinn; Margaret Moloney; Shirley Taylor; Jean-Pierre Y Scheerlinck; Philip Sutton
Journal:  Vaccine       Date:  2010-01-20       Impact factor: 3.641

6.  Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus.

Authors:  M L Clements; R F Betts; E L Tierney; B R Murphy
Journal:  J Clin Microbiol       Date:  1986-07       Impact factor: 5.948

7.  Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine.

Authors:  Denise Nardelli-Haefliger; Floriana Lurati; Daniel Wirthner; François Spertini; John T Schiller; Douglas R Lowy; Françoise Ponci; Pierre De Grandi
Journal:  Vaccine       Date:  2005-05-25       Impact factor: 3.641

8.  Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine.

Authors:  R B Belshe; W C Gruber; P M Mendelman; H B Mehta; K Mahmood; K Reisinger; J Treanor; K Zangwill; F G Hayden; D I Bernstein; K Kotloff; J King; P A Piedra; S L Block; L Yan; M Wolff
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

Review 9.  Complications of seasonal and pandemic influenza.

Authors:  Michael B Rothberg; Sarah D Haessler
Journal:  Crit Care Med       Date:  2010-04       Impact factor: 7.598

Review 10.  Biomedical applications of sheep models: from asthma to vaccines.

Authors:  Jean-Pierre Y Scheerlinck; Kenneth J Snibson; Vernon M Bowles; Philip Sutton
Journal:  Trends Biotechnol       Date:  2008-03-18       Impact factor: 19.536

View more
  12 in total

1.  ISCOMATRIX™ adjuvant reduces mucosal tolerance for effective pulmonary vaccination against influenza.

Authors:  Andrea A Timothy; Ana Tokanovic; Kenneth J Snibson; Stirling J Edwards; Martin J Pearse; Jean-Pierre Y Scheerlinck; Philip Sutton
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 2.  Mucosal vaccine delivery: Current state and a pediatric perspective.

Authors:  Akhilesh Kumar Shakya; Mohammed Y E Chowdhury; Wenqian Tao; Harvinder Singh Gill
Journal:  J Control Release       Date:  2016-02-06       Impact factor: 9.776

Review 3.  Microneedle and mucosal delivery of influenza vaccines.

Authors:  Sang-Moo Kang; Jae-Min Song; Yeu-Chun Kim
Journal:  Expert Rev Vaccines       Date:  2012-05       Impact factor: 5.217

4.  Longevity of Sm-p80-specific antibody responses following vaccination with Sm-p80 vaccine in mice and baboons and transplacental transfer of Sm-p80-specific antibodies in a baboon.

Authors:  Weidong Zhang; Gul Ahmad; Loc Le; Juan U Rojo; Souvik Karmakar; Kory A Tillery; Workineh Torben; Raymond T Damian; Roman F Wolf; Gary L White; David W Carey; Darrick Carter; Steven G Reed; Afzal A Siddiqui
Journal:  Parasitol Res       Date:  2014-04-12       Impact factor: 2.289

5.  Adjuvantation of Pulmonary-Administered Influenza Vaccine with GPI-0100 Primarily Stimulates Antibody Production and Memory B Cell Proliferation.

Authors:  Harshad P Patil; José Herrera Rodriguez; Jacqueline de Vries-Idema; Tjarko Meijerhof; Henderik W Frijlink; Wouter L J Hinrichs; Anke Huckriede
Journal:  Vaccines (Basel)       Date:  2017-07-27

6.  Enhancement of the immunogenicity and protective efficacy of a mucosal influenza subunit vaccine by the saponin adjuvant GPI-0100.

Authors:  Heng Liu; Harshad P Patil; Jacqueline de Vries-Idema; Jan Wilschut; Anke Huckriede
Journal:  PLoS One       Date:  2012-12-17       Impact factor: 3.240

7.  Mucosal vaccine adjuvants update.

Authors:  Joon Haeng Rhee; Shee Eun Lee; Soo Young Kim
Journal:  Clin Exp Vaccine Res       Date:  2012-07-31

8.  Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates.

Authors:  Joseph R Francica; Barbara J Flynn; Kathryn E Foulds; Amy T Noe; Anne P Werner; Ian N Moore; Matthew Gagne; Timothy S Johnston; Courtney Tucker; Rachel L Davis; Britta Flach; Sarah O'Connell; Shayne F Andrew; Evan Lamb; Dillon R Flebbe; Saule T Nurmukhambetova; Mitzi M Donaldson; John-Paul M Todd; Alex Lee Zhu; Caroline Atyeo; Stephanie Fischinger; Matthew J Gorman; Sally Shin; Venkata Viswanadh Edara; Katharine Floyd; Lilin Lai; Seyhan Boyoglu-Barnum; Renee Van De Wetering; Alida Tylor; Elizabeth McCarthy; Valerie Lecouturier; Sophie Ruiz; Catherine Berry; Timothy Tibbitts; Hanne Andersen; Anthony Cook; Alan Dodson; Laurent Pessaint; Alex Van Ry; Marguerite Koutsoukos; Cindy Gutzeit; I-Ting Teng; Tongqing Zhou; Dapeng Li; Barton F Haynes; Peter D Kwong; Adrian McDermott; Mark G Lewis; Tong Ming Fu; Roman Chicz; Robbert van der Most; Kizzmekia S Corbett; Mehul S Suthar; Galit Alter; Mario Roederer; Nancy J Sullivan; Daniel C Douek; Barney S Graham; Danilo Casimiro; Robert A Seder
Journal:  Sci Transl Med       Date:  2021-07-27       Impact factor: 19.319

9.  An avian influenza A (H7N9) virus vaccine candidate based on the fusion protein of hemagglutinin globular head and Salmonella typhimurium flagellin.

Authors:  Li Song; Dan Xiong; Xilong Kang; Yun Yang; Jing Wang; Yaxin Guo; Hui Xu; Sujuan Chen; Daxin Peng; Zhiming Pan; Xinan Jiao
Journal:  BMC Biotechnol       Date:  2015-08-19       Impact factor: 2.563

10.  Effective pulmonary delivery of an aerosolized plasmid DNA vaccine via surface acoustic wave nebulization.

Authors:  Anushi E Rajapaksa; Jenny J Ho; Aisha Qi; Rob Bischof; Tri-Hung Nguyen; Michelle Tate; David Piedrafita; Michelle P McIntosh; Leslie Y Yeo; Els Meeusen; Ross L Coppel; James R Friend
Journal:  Respir Res       Date:  2014-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.